دورية أكاديمية
أعرض في EDS

Acquired lipodystrophy associated with immune checkpoint inhibitors.

التفاصيل البيبلوغرافية
العنوان: Acquired lipodystrophy associated with immune checkpoint inhibitors.
المؤلفون: Gnanendran SS; Dermatology Department, The Canberra Hospital.; Medical School, Australian National University., Miller JA; Dermatology Department, The Canberra Hospital.; Medical School, Australian National University., Archer CA; Canberra Region Cancer Centre, The Canberra Hospital, Canberra, Australian Capital Territory., Jain SV; Dermatology Department, The Canberra Hospital.; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia., Hwang SJE; Dermatology Department, The Canberra Hospital.; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia., Peters G; Medical School, Australian National University.; Canberra Region Cancer Centre, The Canberra Hospital, Canberra, Australian Capital Territory., Miller A; Dermatology Department, The Canberra Hospital.; Medical School, Australian National University.
المصدر: Melanoma research [Melanoma Res] 2020 Dec; Vol. 30 (6), pp. 599-602.
نوع المنشور: Case Reports; Journal Article; Systematic Review
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 9109623 Publication Model: Print Cited Medium: Internet ISSN: 1473-5636 (Electronic) Linking ISSN: 09608931 NLM ISO Abbreviation: Melanoma Res Subsets: MEDLINE
أسماء مطبوعة: Publication: London : Lippincott Williams & Wilkins
Original Publication: Oxford, UK : Rapid Communications of Oxford, 1991-
مواضيع طبية MeSH: Immune Checkpoint Inhibitors/*adverse effects , Lipodystrophy/*chemically induced , Melanoma/*complications , Skin Neoplasms/*complications, Female ; Humans ; Melanoma/drug therapy ; Middle Aged ; Skin Neoplasms/drug therapy
مستخلص: Immune checkpoint inhibitors have become the mainstay of treatment for metastatic melanoma. This article presents a new case of acquired generalised lipodystrophy (AGL) during anti-programmed cell death-1 (anti-PD-1) therapy and a systematic review of the literature with an aim to further understand the pathogenesis. A comprehensive search was conducted using PubMed, Embase, MEDLINE and Cochrane Central databases. We identified four cases of lipodystrophy associated with anti-PD-1 immunotherapy, including our own. Of these, three were associated with nivolumab, and one with pembrolizumab. Body composition changes occurred at a median of 7 months after anti-PD-1 initiation. All cases reported AGL, with subcutaneous fat loss affecting majority of the body. There were three reported cases of insulin resistance associated with AGL. AGL should be a recognised adverse event associated with anti-PD-1 therapy.
References: Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018; 50:165.
Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012; 12:298–306.
Vano YA, Petitprez F, Giraldo NA, Fridman WH, Sautès-Fridman C. Immune-based identification of cancer patients at high risk of progression. Curr Opin Immunol. 2018; 51:97–102.
Lima JG, Nobrega LHC, Lima NN, Dos Santos MCF, Silva PHD, Baracho MFP, et al. Causes of death in patients with berardinelli-seip congenital generalized lipodystrophy. PLoS One. 2018; 13:e0199052.
Hussain I, Garg A. Lipodystrophy syndromes. Endocrinol Metab Clin North Am. 2016; 45:783–797.
Brown RJ, Araujo-Vilar D, Cheung PT, Dunger D, Garg A, Jack M, et al. The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J Clin Endocrinol Metab. 2016; 101:4500–4511.
Haddad N, Vidal-Trecan T, Baroudjian B, Zagdanski A-M, Arangalage D, Battistella M, et al. Acquired generalized lipodystrophy under immune checkpoint inhibition. Br J Dermatol. 2019; 182:477–480.
Falcao CK, Cabral MCS, Mota JM, Arbache ST, Costa-Riquetto AD, Muniz DQB, et al. Acquired lipodystrophy associated with nivolumab in a patient with advanced renal cell carcinoma. J Clin Endocrinol Metab. 2019; 104:3245–3248.
Jehl A, Cugnet-Anceau C, Vigouroux C, Legeay AL, Dalle S, Harou O, et al. Acquired generalized lipodystrophy: a new cause of anti-PD-1 immune-related diabetes. Diabetes Care. 2019; 42:2008–2010.
Lai HC, Lin JF, Hwang TIS, Liu YF, Yang AH, Wu CK. Programmed cell death 1 (PD-1) inhibitors in renal transplant patients with advanced cancer: a double-edged sword? Int J Mol Sci. 2019; 20:1–12.
Araújo-Vilar D, Santini F. Diagnosis and treatment of lipodystrophy: a step-by-step approach. J Endocrinol Invest. 2019; 42:61–73.
Chiquette E, Oral EA, Garg A, Araújo-Vilar D, Dhankhar P. Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges. Diabetes Metab Syndr Obes. 2017; 10:375–383.
Simha V, Garg A. Lipodystrophy: lessons in lipid and energy metabolism. Curr Opin Lipidol. 2006; 17:162–169.
Kudchadkar RR, Michielin O, van Akkooi ACJ. Practice-changing developments in stage III melanoma. Am Soc Clin Oncol Educ Book. 2018759–762.
Haque WA, Shimomura I, Matsuzawa Y, Garg A. Serum adiponectin and leptin levels in patients with lipodystrophies. The Journal of Clinical Endocrinology & Metabolism. 2002; 87:2395–2398.
Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001; 86:1930–1935.
Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004; 350:1220–1234.
Misra A, Garg A. Clinical features and metabolic derangements in acquired generalized lipodystrophy. Medicine (Baltimore). 2003; 82:129–146.
Sinha G. Leptin therapy gains FDA approval. Nat Biotechnol. 2014; 32:300–302.
المشرفين على المادة: 0 (Immune Checkpoint Inhibitors)
تواريخ الأحداث: Date Created: 20200307 Date Completed: 20210805 Latest Revision: 20210805
رمز التحديث: 20231215
DOI: 10.1097/CMR.0000000000000660
PMID: 32141964
قاعدة البيانات: MEDLINE
الوصف
تدمد:1473-5636
DOI:10.1097/CMR.0000000000000660